All In Biotech

Drug Trial Radar · NCT07239102

Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis

A Real-World Clinical Retrospective Study of Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis

Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

300

Actual

Start

Jan 1, 2020

Primary completion

May 1, 2025

Study completion Oct 1, 2025

Sponsor

Lead sponsor
Beijing Tiantan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 20, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a clinical retrospective study that will collect and analyze clinical data from all patients treated with fumeitinib mesylate in the Oncology Department of Tiantan Hospital between January 1, 2020 and May 31, 2025. The data collection will include general demographic characteristics (gender, age, family history, smoking history, etc.), clinicopathological features, NGS test reports, fumeitinib initiation time and dosage, concomitant medications, local treatments (surgery, radiotherapy, etc.), and baseline and follow-up imaging examinations related to efficacy and safety. The study will conduct: 1) clinical data analysis; and 2) exploration of resistance-related clinical characteristics and influencing factors.

Conditions

  • EGFR Positive Non-small Cell Lung Cancer
  • Central Nervous System Metastasis
  • Leptomeningeal Metastasis

Interventions

  • FirmonertinibDrug

    Firmonertinib any dose, oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. iPFSTime frame: From first dose until the event of interest, assessed between January 1, 2020 and May 30, 2025

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Li Xiaoyan

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.